Search the Newsreel

Scancell merges with Nasdaq shell Neuphoria to fund USD 89m Phase III melanoma trial

UK-based Scancell Holdings plc has announced an all-share merger agreement with Neuphoria Therapeutics Inc., a move that will provide Scancell with a Nasdaq listing and up to $89 million in financing. This funding is earmarked for the registrational Phase III development of Scancell's melanoma …

Neuphoria Therapeutics (NEUP) Gains 3.55% as Stock Tests Key Resistance Near $4.14 - Early Entry Signals

Neuphoria Therapeutics (NEUP) Gains 3.55% as Stock Tests Key Resistance Near $4.14 - Stock Analysis

Neuphoria Therapeutics Inc (NEUP) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Neuphoria Therapeutics Inc (NEUP), noting its current score of 1.18, ranking 321 out of 384 in the Biotechnology & Medical Research industry. The company's beta of 0.73 indicates it tends to underperform during rising markets but experiences …

Scancell, Neuphoria Agree to All-Share Merger

Biotech companies Scancell Holdings Plc and Neuphoria Therapeutics Inc. have agreed to an all-share merger, leading to the combined entity listing on Nasdaq and an additional $89 million in financing. This merger aims to fund a crucial Phase 3 clinical trial for Scancell's melanoma …

Advising Nasdaq-listed Neuphoria Therapeutics Inc. on its USD250M merger with AIM-listed Scancell Holdings

Winston Taylor is advising Nasdaq-listed Neuphoria Therapeutics Inc. on its $250 million all-share merger with AIM-listed Scancell Holdings plc, which also involves an $89 million equity and debt financing package. This merger will enable the combined entity, operating under the Scancell name, to fund …

Halper Sadeh LLC is Investigating Whether SAFT, NEUP, NRIM are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating Safety Insurance Group Inc. (SAFT), Neuphoria Therapeutics Inc. (NEUP), and Northrim BanCorp, Inc. (NRIM) for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that the proposed transactions …

Neuphoria Therapeutics Inc. Revenue Breakdown – NASDAQ:NEUP

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) generated $15.65 million USD in revenue last year, primarily from its Allosteric Ion Channel Modulators segment. This segment also contributed $15.65 million USD to the revenue, marking a significant increase from $14.83 thousand USD in the prior year. The United …

NEUP|Neuphoria Therapeutics Inc|Price:3.810|Chg%:+0.170

Neuphoria Therapeutics Inc. (NEUP) is a clinical-stage biopharmaceutical company focused on developing novel treatments for central nervous system disorders. Their lead candidate, BNC210, is an allosteric ion channel modulator for social anxiety and PTSD, designed to offer rapid relief without common side effects like …

Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Neuphoria Therapeutics Inc's (NEUP) dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years and currently shows no disclosed dividend payment data. The stock's current trading information and …

Neuphoria Therapeutics Inc (NEUP) Income Statement

Neuphoria Therapeutics Market Sentiment

This article provides an overview of Neuphoria Therapeutics (NEUP) market sentiment, highlighting key signals such as analyst consensus, short interest, options flow, and insider activity. It details recent analyst ratings, including upgrades and downgrades, and reports a significant insider purchase of shares. The article …

Neuphoria Therapeutics Inc (NEUP) Institutional Confidence

This article provides details on the institutional confidence score for Neuphoria Therapeutics Inc (NEUP), showing a current score of 3.00, unchanged from the previous score. It lists the top institutional shareholders, their shareholdings, and the percentage change in their holdings. The data was updated …

NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) and Scancell Holdings plc. The firm is concerned that Neuphoria shareholders, who will own 14.5% of the combined company, may not be receiving a fair price …

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

Monteverde & Associates PC, a class action litigation firm, has announced an investigation into Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) following its proposed merger with Scancell Holdings plc. The firm is examining whether the deal is fair to Neuphoria stockholders, who are expected to own …

Neuphoria Therapeutics (NEUP) Proxy filing Summary

Neuphoria Therapeutics (NEUP) has filed a proxy summary detailing an all-share merger between two biotech firms, aiming to create a combined entity focused on immunotherapies with a Nasdaq listing and continued AIM listing. The merger structure allocates 85.5% ownership to the acquiring company's shareholders …

Neuphoria Therapeutics (Nasdaq: NEUP) to be acquired by Scancell

Neuphoria Therapeutics (Nasdaq: NEUP) has agreed to an all-share merger with UK-based Scancell Holdings plc, where Neuphoria will become an indirect wholly-owned subsidiary of Scancell. The deal involves Neuphoria stockholders receiving Scancell American Depositary Shares and contingent value rights (CVRs), with existing Neuphoria stockholders …

NEUPHORIA THERAPEUTICS - SCANCELL EXPECTS TO SECURE UP TO $89 MLN IN FINANCING

Scancell Holdings plc, a clinical-stage immunotherapeutics company, announced that its subsidiary, Neuphoria Therapeutics, is expected to secure up to $89 million in financing from a newly formed independent entity. The financing involves an initial $29 million for Neuphoria's operational expenses, with an additional $60 …

Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell

Neuphoria Therapeutics has entered into an agreement for an all-share takeover by Scancell. This acquisition will see Scancell issue new ordinary shares to Neuphoria shareholders, valuing Neuphoria at approximately £20 million. The move is expected to expand Scancell's dermatology pipeline and leverage Neuphoria's innovative …

Scancell, Neuphoria Therapeutics Agree All-share Merger

Scancell Holdings PLC announced an all-share merger agreement with Neuphoria Therapeutics, a private biotechnology company. Under the terms, Neuphoria shareholders will receive new Scancell shares, valuing Neuphoria at GBP22.5 million. The deal aims to combine Scancell's cancer immunology expertise with Neuphoria's neurology focus, creating …

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

Scancell Holdings plc and Neuphoria Therapeutics Inc. have announced an all-share merger where Scancell will acquire Neuphoria, with the combined entity operating as Scancell and seeking a Nasdaq listing. The merger aims to advance Scancell's pipeline of targeted immunotherapies, particularly funding the global registrational …

Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

Scancell Holdings PLC is set to merge with US biotech Neuphoria Therapeutics, gaining a Nasdaq listing and access to US investors for its cancer immunotherapy pipeline. The combined entity will retain the Scancell name and aims for an $89 million funding package to support …

Price to earnings forward of Neuphoria Therapeutics Inc. – NASDAQ:NEUP

This article provides a brief overview of the "Price to earnings forward" for Neuphoria Therapeutics Inc. (NASDAQ: NEUP) as displayed on an investment platform. It indicates that the specific financial value for this metric is currently unavailable or not presented in the snippet. The …

NEUP Q1 2026 Earnings: EPS Surprise of 90.9% Signals Progress Amid Pre-Revenue Stage - Mid-Term Outlook

Neuphoria Therapeutics Inc. (NEUP) Q1 2026 Earnings: EPS Surprise of 90.9% as Losses Narrow Significantly - Annual Report

NEUP Q1 2026 Earnings: EPS Surprises with 90.9% Beat Amid No Revenue - Guidance Accuracy Score

Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis

Neuphoria Therapeutics Inc. (NEUP) Live Share Price, Invest From India

Neuphoria Therapeutics Inc. (NEUP) reports earnings

Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics Inc. (NEUP) Earnings, Actual EPS, EPS Estimates & Results